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Background/aim: Needle phobia occurs in more than half of diabetic patients due to the pain caused by frequent insulin injections.
Therefore, this study evaluated the effect of topically administered lavender aromatherapy on the pain of insulin injections in diabetic
patients.
Materials and methods: In this double-blind randomized controlled and experimental study, patients who met the study criteria were
divided into three groups; topical lavender oil (n = 60), placebo (n = 60), and control (n = 60) groups. The data were collected using the
“Patient Information Form”, the “Follow-up Form”, the “Verbal Category Scale (VCS)”, and the “Visual Analogue Scale (VAS)”.
Results: The results revealed no significant difference between the patients in the topical lavender oil group before and during the
insulin injection in terms of VAS and VCS pain scores (p > 0.05). In the placebo and control groups, the mean VAS and VCS pain scores
during insulin injection were found to be significantly higher than before insulin injection (p < 0.05). Besides, the mean VAS and VCS
scores during insulin injection were significantly higher in the placebo and control groups than the topical lavender oil group (p < 0.05).
Conclusion: The study showed that patients who were administered topical lavender oil felt less pain after insulin injection than those
in the placebo and control groups. Therefore, topically applied lavender aromatherapy can be easily used for pain control in insulindependent diabetic patients (clinical trial number NCT04767737).
Key words: Pain, aromatherapy, topical lavender oil, subcutaneous injections

1. Introduction
Diabetes Mellitus (DM) is a serious chronic disease that
negatively affects the quality of life.1 The rapid increase
in its prevalence both in our country and around the
world has made diabetes a significant health problem in
developed and developing countries.1,2 It is reported that
approximately three-quarters (79%) of diabetic patients
are reported to live in low and middle-income countries.3
According to the International Diabetes Federation’s (IDF)

2019 data, 1 out of every 11 people in the world is diabetic.
It is stated that the number of diabetic patients, which is
463 million in the world between the ages of 20–79 in 2019,
will reach 700 million by 2045, with an increase of 51%.4
It is estimated that this number will reach 16.5 million in
2045 (12.8 million in 2017) in Turkey, and it will become
one of the top 10 countries in terms of diabetes.2
To control the course of the disease and to reduce
its complications, insulin treatment is planned for the
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whole life of Type 1 diabetic patients, and frequently for
approximately 40% of Type 2 diabetic patients [1–4].
Frequent or incorrect administration of insulin injections
may lead to the development of complications such as
regional pain, ecchymosis, or hematoma on the injection
site. It is emphasized that the pain caused by repeated
insulin injections negatively affects the psychological wellbeing of the individuals as well as their physical comfort.
Besides, such problems make it challenging to administer
repeated injections safely [5–7].
Perception of pain involves various mental processes,
such as the individual’s feelings and beliefs about pain [8].
Therefore, early pain experience leads to the development
of needle phobia and a poor attitude towards treatment
[9]. In a relevant study, 58.5% of diabetic patients were
found to have a fear of pain due to insulin injections [10].
Pain control is one of the main tasks of nurses [11].
By alleviating pain, the patient’s acceptance of treatment
increases, and thus the quality of life improves [12].
Therefore, nurses should seek different ways of effective
pain control. In this sense, complementary therapies are
continuously evolving within the health system [13]. The
use of complementary therapies reduces the development
of complications and the need for synthetic analgesics [14].
In the literature, lavender is reported to have the ability to
heal burns and insect bites [15] as well as analgesic [16–18],
wound healing [19], antibacterial, antifungal, sedative, and
antidepressant effects. The main components of lavender
(Lavandula angustifolia) essential oil, such as lavender
and linalyl acetate, and linalool, are also recommended as
topical analgesics in animal models [20].
Whatever the cause, acute pain is a serious problem
for individuals with chronic illnesses. Therefore, this study
evaluated the effect of topically administered lavender
aromatherapy on the pain of insulin injections in diabetic
patients.
2. Materials and method
2.1. Research type
This study is in a double-blind randomized controlled
and experimental design and was conducted with diabetic
patients receiving insulin therapy.
2.2. Setting and time of the study
The study was carried out at the Internal Medicine Service
of the TR Ministry of Health X Y State Hospital between
May 2020 and July 2020.
2.3. The Universe and sample of the research
The population of the research consisted of insulindependent diabetic patients over the age of 18 who were
hospitalized at the Internal Medicine Service of the TR The
Ministry of Health X Y State Hospital between May 2020
and July 2020.
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The sample was determined as 159 (53 for each
group) patients for three groups (lavender oil group,
placebo group, control group) by using the power analysis
method (G*Power 3.1.9.6 program), with the margin of
error α = 0.05, 0.25 medium effect size, and 0.80 (80%)
target strength of the test. However, 7 patients who met
the study inclusion criteria were added to each group (60
in the lavender oil group, 60 in the placebo group, 60 in
the control group) in case some of the participants quit
the study for any reason (Figure). While the patients were
randomized, different application groups (topical lavender
oil, placebo, control group) were determined by lot in
different months (May, June, and July) to minimize the
possibility of being affected by each other.
2.4. Levander oil
‘Talya’ brand (Talya Herbal Products Tic. San. Ltd. Şti.,
Antalya, Turkey) 100% pure L. angustifolia oil, analyzed
in the laboratory of Talya Kimya, was used in the patients.
That is, lavender oil was a commercial product supplied
from the market.
2.5. Inclusion and exclusion criteria of the study
Inclusion criteria for the patients were;
1. being 18 years of age or older,
2. having Type-1 DM or Type-2 DM disease,
3. being conscious and communicating, not having
mental and cognitive impairment,
4. not having eczema and fragrance allergy to
lavender,
5. not having an alcohol or narcotic addiction,
6. not having a head injury or convulsion history,
7. not having diabetes-related neuropathy, and
8. if the patient took sedatives or analgesics, at least 6
hour would pass,
Exclusion criteria for the patients were;
1. having a history of addiction or diagnosed
psychological disorders,
2. having an unstable hemodynamic status,
3. having skin disease symptoms such as wounds and
eczema at the insulin injection site and,
4. having an allergy to lavender.
To determine whether the patients in the topical
lavender oil group had allergies to lavender oil, 1 drop
of 100% lavender oil was dropped on a small area on the
inner side of their arms to examine the development of
skin reactions such as redness, itching, pain, burning, and
sensitivity [21,22]. Patients experiencing these symptoms
of reaction were excluded from the study.
2.6. Applications for topical lavender oil, placebo, and
control groups
Since this study was a double-blind randomized controlled
study, no information about the drug (topical lavender
oil, topical water) was given to the nurse (researcher) who
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gave insulin injection, and the patient to reduce bias. The
drug to be used was applied in spray bottles without any
labels.
Before the administration, pain level, blood pressure,
respiratory rate, pulse rate, oxygen saturation level (SPO2),
and blood glucose of all patients (topical lavender oil,
placebo, and control groups) were measured, and then, 3
puffs (0.3 mL) of 100% lavender (L. angustifolia) essential
oil to the topical lavender oil group and 3 puffs (0.3 mL) of
topical distilled water to the placebo group were sprayed on
the arms of the patients. No application was applied to the
control group. Five minute later, the insulin injection site was
wiped with 10% povidone-iodine (baticonol) in all patients,
and the injection was given. During the administration of

Enrollment

the insülin, the pain levels of the patients were measured
again. After giving the injection, blood pressure, respiratory
rate, pulse rate, oxygen saturation level, and blood glucose
of the patients were also measured again.
To ensure consistency, an insulin injector of 30 gauge
and 8 mm needle length (BD Micro-Fine Plus brand) was
used, and insulin was applied at a 90° angle by grasping the
patient’s arm by hand. During the study, the applications
were made to all three groups by the same researcher. One
drop of 100% lavender oil was dropped to the researcher’s
collar before applying and injecting insulin to all groups
so that s/he does not understand what is applied in
which group. Besides, the same site (back of the arm) was
preferred for all patients for injection.

Assessed for eligibility (n=288)
Excluded (n= 108)
- Not meeting inclusion criteria
(n=86)
- Declined to participate (n=22)
- Other reasons (n=0)
Randomized (n= 180)

Allocation
Allocated to Topical lavender
oil group (n= 60)
-Received allocated
intervention (n= 60)
- Did not receive allocated
intervention (n= 0)

Allocated to Placebo group
(n= 60)
- Received allocated
intervention (n= 60)
- Did not receive allocated
intervention (n= 0)

Allocated to intervention
(n= 60)
-Received allocated
intervention (n= 60)
- Did not receive allocated
intervention (n= 0)

Lost to follow-up (n= 0)
Discontinued intervention
(n= 0)

Lost to follow-up (n= 0)
Discontinued intervention
(n= 0)

Analysed (n= 60)
- Excluded from analysis
(n= 0)

Analysed (n= 60)
-Excluded from analysis
(n= 0)

Follow-up
Lost to follow-up (n= 0)
Discontinued intervention
(n= 0)

Analysis
Analysed (n= 60)
- Excluded from analysis
(n= 0)
Figure. The study flow diagram.

Figure 1. The study CONCORT flow diagram
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2.7. Data collection forms and administration procedure
To collect the data, the “Patient Information Form”
including information about patients’ sociodemographic
and medical conditions, the “Topical Lavender Oil/
Placebo/Control Group Follow-up Form”, the “Verbal
Category Scale (VCS)” and the “Visual Analogue Scale
(VAS)” were used.
The patient information form was developed by the
researchers after reviewing the literature [21,22]. It took
approximately 10 min to fill in the form by interviewing
each patient before the administration of insulin. The
questions in the patient information form were asked
to the patients by the researcher, and the answers were
recorded in the form. This form includes two parts.
The first part consists of six questions to determine the
sociodemographic characteristics of the patients (gender,
age, education, marital status, occupation, income
perception level).
The second part includes six questions investigating the
“medical condition of patients” including diabetes type,
duration of diabetes, insulin treatment duration, allergy
status, the reason for hospitalization, and the presence of
comorbid chronic disease, etc.
The topical lavender oil/placebo/control group
follow-up form was developed by the researchers to
record the pain level (VAS and VCS), blood pressure,
respiratory rate, pulse rate, oxygen saturation level, and
blood glucose level of the patients before and after the
insülin administration.
Verbal category scale (VCS) is based on the patient’s
choice of the most appropriate word to identify his/her
pain [23]. Accordingly, the patient was asked to rate his/
her pain between 0–4 as 0; no pain, 1: mild pain, 2: severe
pain, 3: very severe pain, 4: unbearable pain.
Visual analogue scale (VAS) is used to digitalize the
pain level that cannot be measured numerically. A line
with a length of 100 mm has the words “no pain” at one end
and “the most unbearable pain” on the other. The patient
indicates his/her pain by choosing the most appropriate
place on the line. Then, the level of pain experienced by the
patient is determined by using a scale with scores between
0–10. According to this scoring system, less than 3 points
indicate mild pain, 3–6 points indicate moderate pain, and
more than 6 points indicate severe pain [24].
2.8. Ethical considerations
To conduct the study, required permission was received
from Gümüşhane Provincial Health Directorate for
Gümüşhane X Hospital (dated 15/06/2020 and numbered
62876282-044-E.1590) and Gümüşhane University Ethics
Committee (2020/5 number and 05/05/2020) and was
registered with reference number NCT04767737 in the
clinical trial management system. Besides, all participants
gave informed consent prior to their inclusion in the study
after they were informed about the study.
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2.9. Evaluation of data
Statistical Package for Social Science (SPSS) 24.0 program
was used for statistical evaluation of the results. According
to the Kolmogorov-Smirnov test based on the number of
samples, it was determined that the data were normally
distributed. The data were presented as mean, percentage,
and standard deviation. Paired sample t-test in the
dependent groups, one-way ANOVA test, and post hoc
Tukey test in the independent groups and chi-square
were used to analyze the data. p < 0.05 was considered as
statistically significant.
2.10. Conflict of interest and financing
In this study, there is no conflict of interest between the
authors or with any company. This study was not supported
by any research fund.
3. Results
This study was conducted with 180 patients who met the
research criteria. More than half of the participants in
the study were male (52.2%), the majority of them were
married (71.1%), they had primary school education and
below (66.7%), 38.3% of them were farmers, and most of
them had Type 2 diabetes (81.1%). Almost no participants
had any allergies (90.6%), and half had comorbid chronic
disease other than diabetes (50.0%) (Table 1).
The chi-square test, which was used to compare the
topical lavender oil, placebo, and control group patients
according to their sociodemographic characteristics,
revealed no statistically significant difference in terms
of gender, marital status, education level, diabetes type,
allergy status, and having a comorbid chronic disease
(p > 0.05). A statistically significant difference was
found between the distribution of patients in the topical
lavender oil, placebo, and control groups in terms of their
occupations (X2 = 10.633; p = 0.031) (p > 0.05) (Table 1).
The distribution of the patients in the topical lavender
oil, placebo, and control groups according to their medical
conditions and vital signs is presented in Table 2. The
mean age of the participants in the study was 52.82 ± 13.48
years, the mean blood glucose level was 172.74 ± 44.54
mg/dL, the mean duration of diabetes was 14.37 ± 12.22
years, and the mean duration of insulin use was 9.13 ±
12.24 years. The mean measurements of the patients before
topical lavender oil application and insulin injection were
as follows; systolic blood pressure 117.63 ± 19.50 mm/
Hg, diastolic blood pressure 71.16 ± 10.47 mm/Hg, pulse
rate 86.86 ± 17.29 min, respiration 21.67 ± 2.52 min, SPO2
97.47 ± 5.72 (%), the VCS was 0.46 ± 0.67, and the VAS was
0.88 ± 1.09. After the insulin injection, the mean systolic
blood pressure was found to be 116.27 ± 13.75 mm/Hg,
the mean diastolic blood pressure was 71.97 ± 8.72 mm/
Hg, the mean pulse rate was 87.81 ± 13.77 min, the mean
respiratory rate was 21.49 ± 2.00 min, and the mean SPO2
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was 97.97 ± 1.37 (%). During the insulin injection, the
mean VCS was determined to be 1.09 ± 0.78, and the mean
VAS was 2.16 ± 1.72 (Table 2).
The results of the one-way ANOVA and post hoc
analysis tests for the comparison of topical lavender oil,
placebo, and control groups according to the medical
condition and vital signs of the patients showed that
the mean diastolic blood pressure of the patients in the
control group (75.83 ± 8.29) after insulin injection was
significantly higher than topical lavender oil (70.50 ± 8.71)
and placebo (69.58 ± 7.93) group (F = 9.869; p = 0.000)
(p < 0.05). Post hoc analysis showed that this significance
between them was due to the control group. It was also
determined that the mean respiration after insulin
injection was significantly higher in the control group
(22.41 ± 1.70) than the topical lavender oil (21.06 ± 2.23)
and placebo (21.00 ± 1.73) groups (F = 10.532; p = 0.000)
(p < 0.05). Post hoc analysis showed that this significance
between them was due to the control group and placebo
group. Besides, after insulin injection, the mean SPO2 was
statistically significantly lower in the control group (97.36
± 1.30) compared to the topical lavender oil (98.55 ± 1.32)
and placebo (98.00 ± 1.24) groups (F = 12.633; p = 0.000)
(p < .05). Post hoc analysis showed that this significance
between them was due to the control group.

The mean VCS score, which shows the severity of pain
during insulin injection, was significantly lower in the
topical lavender oil group (0.55 ± 0.64) compared to the
placebo (1.25 ± 0.68) and control (1.48 ± 0.72) groups (F
= 30.157; p = 0.000) (p < 0.05). A significant difference
was also seen in the mean VAS scores, which shows the
severity of pain during insulin administration, among the
topical lavender oil group (1.10 ± 1.28), the placebo group
(2.27 ± 1.53), and the control group (3.12 ± 1.70) (F =
26.597; p = 0.000) (p < 0.05). The post hoc analysis showed
that this difference was caused by the placebo and control
groups (Table 2).
The one-way ANOVA test performed for the
comparison of the medical condition and vital signs
of the patients in the topical lavender oil, placebo, and
control groups revealed no significant difference among
these groups in terms of age, blood glucose, duration of
diabetes, duration of insulin use, systolic blood pressure
before insulin injection, diastolic blood pressure, pulse,
respiration, SPO2, VCS score, VAS score, systolic blood
pressure after insulin injection and the mean pulse rate
after the application (p > 0.05) (Table 2).
Paired sample t-test, which was performed to compare
the mean scores and VCS and VAS before and during
insulin injection of topical lavender oil, placebo, and

Table 1. Distribution of the sociodemographic and disease-related characteristics of diabetic patients (n = 180).
N (%)
Variable

Chi-square test

Topical
Plasebo
lavender oil

Control

Total

Male

34(56.7)

29(48.3)

31(51.7)

94(52.2)

Female

26(43.3)

31(51.7)

29(48.3)

86(47.8)

Married

45(75.0)

43(71.7)

40(66.7)

128(71.1)

Single (divorced/widow(er))

15(25.0)

17(28.3)

20(33.3)

52(28.9)

Primary+secondary school and below 45(75.0)

38(63.3)

37(61.7)

120(66.7)

High school

10(16.7)

11(18.3)

17(28.3)

38(21.1)

University and above

5(8.3)

11(18.3)

6(10.0)

22(12.2)

Housewife/self-employed/retired

12(20.0)

27(45.0)

18(30.0)

57(31.7)

Farmer

29(46.3)

15(25.0)

25(41.7)

69(38.3)

Worker-civil servant

19(31.7)

18(30.0)

17(28.3)

54(30.0)

Type 1 diabetes

10(16.7)

13(21.7)

11(18.3)

34(18.9)

Type 2 diabetes

50(83.3)

47(78.3)

49(81.7)

146(81.1)

The presence of
allergy

Yes

5(8.3)

7(11.7)

5(8.3)

17(9.4)

No

55(91.7)

53(88.3)

55(91.7)

163(90.6)

The presence of
comorbid disease

Yes

29(48.3)

30(50.0)

31(51.7)

90(50.0)

No

31(51.7)

30(50.0)

29(48.3)

90(50.0)

Gender
Marital status

Education level

Occupation

Type of diabetes

X2

P

0.846

0.655

1.028

0.598

6.031

0.197

10.633 0.031*

0.508

0.776

0.520

0.771

0.133

0.936

*p < 0.05
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Table 2. Distribution of medical status and vital signs results of diabetic patients (n = 180).
Mean ± SD
Variable

One-way ANOVA

Topical lavender oil Placebo

Control

Total

F

P

Age (year)

50.91 ± 13.42

53.80 ± 13.65

53.76 ± 13.41

52.82 ± 13.48

0.903

0.407

Blood glucose (mg/dL)

170.33 ± 49.98

178.45 ± 45.58

169.45 ± 37.31

172.74 ± 44.54

0.742

0.478

Duration of diabetes (year )

14.32 ± 12.93

15.15 ± 12.44

13.65 ± 11.39

14.37 ± 12.22

0.225

0.799

Duration of insulin use (year)

7.87 ± 12.30

10.18 ± 12.77

9.35 ± 11.73

9.13 ± 12.24

0.548

0.579

Systolic BP (mm/Hg) before insulin injection

116.83 ± 20.54

119.41 ± 18.59

116.66 ± 19.54

117.63 ± 19.50

0.372

0.690

Systolic BP (mm/Hg) after insulin injection

116.33 ± 15.29

113.50 ± 11.50

119.00 ± 13.86

116.27 ± 13.75

2.438

0.090

Diastolic BP (mm/Hg) before insulin injection

70.50 ± 9.81

71.16 ± 11.65

71.83 ± 9.99

71.16 ± 10.47

0.241

0.786

Diastolic BP (mm/Hg) after insulin injection

70.50 ± 8.71

69.58 ± 7.93

75.83 ± 8.29

71.97 ± 8.72

9.869

0.000*

Pulse before insulin injection (min)

89.20 ± 18.09

91.41 ± 17.78

88.96 ± 16.10

86.86 ± 17.29

0.364

0.695

Pulse after insulin injection (min)

85.11 ± 14.56

87.51 ± 13.50

90.80 ± 12.82

87.81 ± 13.77

2.620

0.076

Respiration before insulin injection (min)

22.00 ± 2.55

21.56 ± 2.56

21.46 ± 2.45

21.67 ± 2.52

0.757

0.471

Respiration before insulin injection (min)

21.06 ± 2.23

21.00 ± 1.73

22.41 ± 1.70

21.49 ± 2.00

10.532

0.000**

SPO2 before insulin injection (%)

96.60 ± 9.65

97.81 ± 1.73

98.00 ± 1.51

97.47 ± 5.72

1.059

0.349

SPO2 after insulin injection (%)

98.55 ± 1.32

98.00 ± 1.24

97.36 ± 1.30

97.97 ± 1.37

12.633

0.000**

VCS score before insulin injection

0.53 ± 0.72

0.45 ± 0.67

0.40 ± 0.61

0.46 ± 0.67

0.601

0.549

VCS score during insulin injection

0.55 ± 0.64

1.25 ± 0.68

1.48 ± 0.72

1.09 ± 0.78

30.157

0.000**

VAS score before insulin injection

1.07 ± 1.16

0.87 ± 1.09

0.70 ± 1.01

0.88 ± 1.09

1.694

0.187

VAS score during insulin injection

1.10 ± 1.28

2.27 ± 1.53

3.12 ± 1.70

2.16 ± 1.72

26.597

0.000*

BP: Blood pressure , SPO2: Oxygen saturation, VCS: Verbal category scale, VAS: Visual analogue scale *p < 0.001 , ** p < 0.001 and post
hoc Tukey test, Note: In repeated measurements n = 180

control groups, demonstrated that the mean VCS pain
score of the placebo (t = –12.907; p = 0.000), and control
(t = –3.563; p = 0.000) groups increased significantly
during the administration compared to VCS score before
the administration (p < 0.05). The mean VAS pain scores
of the placebo (t = –9.530; p = 0.000) and control (t =
–12.780; p = 0.000) groups during the administration
were also significantly higher than the mean VAS pain
scores before the administration (p < 0.05). However, no
significant difference was found between the mean VCS
and VAS pain scores of the patients in the topical lavender
oil group before and during insulin injection (p > 0.05)
(Table 3).
4. Discussion
This double-blind randomized controlled study
investigated the effect of topically administrated lavender
aromatherapy on the pain of insulin injection in diabetic
patients.
Frequently used in aromatherapy, L. angustifolia,
one of the complementary treatments, contains many
active ingredients. “Linalool” and “linalyl acetate” are
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among these active ingredients, and linalool acts as a
sedative by affecting gamma-aminobutyric acid receptors.
Another active ingredient, linalyl acetate, has a narcotic
function [25]. There are various studies in the literature
examining the effect of aromatherapy on pain caused
by the insertion of an intravenous catheter, injection
insertion into the forearm, or arteriovenous (AV) fistula
application via injection [16,21,22,26–29]. However, no
national or international studies to our knowledge have
investigated the use of topical aromatherapy during
insulin injection in diabetic patients. The vital signs of
the patients in the study were measured as follows before
insulin injection; systolic blood pressure 117.63 ± 19.50
mm/Hg, diastolic blood pressure 71.16 ± 10.47 mm/Hg,
pulse rate 86.86 ± 17.29 min, respiration 21.67 ± 2.52
min, and SPO2 97.47 ± 5.72 (%). Measurements after
insulin injection were found to be as follows; the mean
systolic blood pressure 116.27 ± 13.75 mm/Hg, the mean
diastolic blood pressure 71.97 ± 8.72 mm/Hg, the mean
pulse rate 87.81 ± 13.77 min., the mean respiration 21.49
± 2.00 min, and the mean SPO2 97.97 ± 1.37(%). Besides,
a statistically significant difference was seen between the
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groups in terms of diastolic blood pressure, respiration,
and SPO2. Tüzün Özdemir [22] examined the effect of
aromatherapy on the pain of injection of an AV fistula
and found the mean systolic blood pressure of the patients
participating in the study as 139.99 mm/Hg, the mean
diastolic blood pressure as 81.24 mm/Hg, and the mean
pulse rate as 81.39 min. Contrary to our study, there was
no statistically significant difference between the groups.
That the mean systolic blood pressure and diastolic blood
pressure scores in our study were found to be lower than
those of Tüzün Özdemir’s [22] study is thought to be due
to the effect of aromatherapy on hypertension associated
with cardiovascular disease [30–32]. In parallel with
the literature reviewed, patients in the control group in
this study had significantly higher mean diastolic blood
pressure after insulin injection [22].
In our study, no significant difference was found
between the VCS and VAS pain scores of patients in
the topical lavender oil group before and during insulin
injection. However, it was found that the mean VCS and
VAS pain scores of the patients in the placebo and control
groups during insulin injection were significantly higher
than before insulin injection. In addition, mean VCS and
VAS scores during insulin injection were significantly
higher in the placebo and control groups than in the
topical lavender oil group. Although there was no
significant difference in the mean pain scores before and
during the application of insulin in the topical lavender
oil group (VCS t = –0.228, p = 0.821; VAS t = –0.314, p
= 0.755), we can say that topically applied aromatherapy
was effective in reducing pain due to the statistically
increased pain in the placebo and control groups and the
significant difference in pain scores during the application
of insulin between groups. It is emphasized in the relevant
literature that both inhaler [22,26,33] and topical lavender

oil aromatherapy [34] significantly reduce pain during
AV fistula puncture. In some other studies, lavender
aromatherapy was found to significantly reduce the total
pain score at the 5th and 10th min of intravenous catheter
insertion in both children [28] and adults [29]. In a study
examining the effect of lavender aromatherapy on the
pain felt during the injection, it was reported that inhaled
lavender aromatherapy applied significantly reduced pain
[16]. In an experimental study, Aliasgharpour et al. [21]
measured VAS pain scores by applying 3 consecutive
sessions of lavender aromatherapy in hemodialysis
patients and reported that the pain during puncture of
the arteriovenous fistula was 5.36 ± 2.08, 5.69 ± 2.29, and
5.58 ± 2.15 in the control group, respectively and 4.00 ±
2.48, 3.05 ± 1.94, 2.97 ± 2.27 in the experimental group,
respectively [21]. In another study examining the effect
of lavender aromatherapy on pain during puncture of
arteriovenous fistula, it was reported that the mean VAS
pain severity score in the experimental groups was 3.78
± 0.24 before the application and decreased significantly
to 2.36 ± 0.25 after the application [27]. In our study, the
mean pain score of the topical lavender oil group was
found to be lower than the other studies reviewed. The
reason for this is estimated to be the size of the injection
used during the insulin administration (insulin injector
with 30 gauge and 8 mm length) and the frequency of
insulin application of the patients.
4.1. Limitations
In this study, the short-term effect of lavender essential
oil has been evaluated. Therefore, the findings obtained
are valid for the short-term effect of lavender essential oil
on pain. The results of this study cannot be generalized
because 1 Internal Medicine Service was involved in
the study. Moreover, another limitation is that a placebo
control group was not used in this study.

Table 3. Distribution of diabetes patients’ VCS and VAS mean scores (n = 180).

Variable

Mean ±SD
Topical lavender oil

Placebo

Control

VCS score before insulin injection

0.53 ± 0.72

0.45 ± 0.67

0.40 ± 0.61

VCS score during insulin injection

0.55 ± 0.64

1.25 ± 0.68

1.48 ± 0.72

Paired sample t-test

t = –0.228
P = 0.821

t = –12.907
P = 0.000*

t = –13.563
P = 0.000*

VAS score before insulin injection

1.07 ± 1.16

0.87 ± 1.09

0.70 ± 1.01

VAS score during insulin injection

1.10 ± 1.28

2.27 ± 1.53

3.12 ± 1.70

t = –0.314

t = –9.530

t = –12.780*

P = 0.755

P = 0.000*

P = 0.000*

Paired sample t-test
*p < 0.001
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5. Conclusion
The findings of this study showed that patients who were
applied topical lavender oil during insulin injection felt
less pain than the placebo and control group patients. As a
result, it is concluded that topical lavender aromatherapy
can be easily applied for pain control in insulin-dependent
diabetic patients. Nurses or healthcare professionals are
recommended to regularly assess patients’ pain caused by
insulin administration and include aromatherapy in their
nursing practices.
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